Finance

Lists
Q2 2027 earnings • released • EPS beat +11.98% • Revenue beat +24.63%
See results
NATCOPHARM:NSE
Natco Pharma Ltd
₹819.55
-0.41%
(-3.35) 1D
Nov 18, 3:27:24 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for NATCOPHARM...
Open
₹823.80
High
₹832.85
Low
₹818.10
Mkt. cap
146.80B
Avg. vol.
696.01K
Volume
1.11M
Dividend
0.52%
Quarterly dividend
₹1.06
Ex-dividend date
Oct 1, 2026
P/E ratio
17.87
52-wk high
₹1,216.89
52-wk low
₹773.60
EPS
₹45.88
Shares outstanding
182.26M
No. of employees
4K
Open
₹823.80
High
₹832.85
Low
₹818.10
Mkt. cap
146.80B
Avg. vol.
696.01K
Volume
1.11M
Dividend
0.52%
Quarterly dividend
₹1.06
Ex-dividend date
Oct 1, 2026
P/E ratio
17.87
52-wk high
₹1,216.89
52-wk low
₹773.60
EPS
₹45.88
Shares outstanding
182.26M
No. of employees
4K
News stories
From web sources and news partners
Profile
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs at affordable prices. Wikipedia
About Natco Pharma Ltd
CEORajeev Nannapaneni
Employees4.43K
Founded1981
HeadquartersBanjara Hills, Telangana, India
SectorHealth Care
IndustryPharmaceutical industry
Last report
Nov 13, 2026
Fiscal period
Q2 2027
₹11.31 / ₹10.10
+11.98%beat
Revenue / Est. (INR)
10.19B / 8.18B
+24.63%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
6.47B
7.43B
7.35B
10.19B
Cost of goods sold
1.33B
1.99B
1.48B
1.83B
Cost of revenue
1.33B
1.99B
1.48B
1.83B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.59B
1.63B
1.79B
2.04B
Operating expense
4.02B
4.38B
4.48B
5.76B
Total operating expenses
5.35B
6.37B
5.96B
7.59B
Operating income
1.12B
1.06B
1.39B
2.61B
Other non operating income
581.00M
-2.11B
592.00M
-
EBT including unusual items
1.72B
1.80B
2.70B
2.72B
EBT excluding unusual items
1.72B
2.02B
2.70B
2.72B
Income tax expense
207.00M
-892.00M
634.00M
698.00M
Effective tax rate
12.03%
-49.61%
23.49%
25.62%
Other operating expenses
1.96B
2.23B
2.22B
3.23B
Net income
1.52B
2.68B
2.06B
2.03B
Net profit margin
23.40%
36.08%
28.09%
19.87%
Earnings per share
8.46
14.96
11.53
11.31
Interest and investment income
-
2.33B
-
-
Interest expense
-95.00M
-
-130.00M
-176.00M
Net interest expenses
-95.00M
2.33B
-130.00M
-176.00M
Depreciation and amortization charges
462.00M
504.00M
471.00M
492.00M
EBITDA
1.57B
1.55B
1.91B
3.09B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps